ROIV Roivant Sciences Ltd

$ROIV Vivek sells $1.2 billion worth of shares and then the stock sells off and stifles with downward action. These games are ridiculous!

$ROIV just added. Haven’t added since 12. Looking more and more likely Matt is going to steer this guy into a behemoth.

Stifel🏁 $ROIV and said -- We are initiating coverage of ROIV with a Buy rating and $51 target price. $IMVT $ABUS Stifel added—Our positive thesis is predicated on our view that Roivant via its 'vant' subsidiaries represents a compelling multi-asset story with scarcity value within the specialty autoimmune and idiopathic lung disease markets. With the recent approval of Lisraya (Brepocitinib) in dermatomyositis, positive Ph2 PH-ILD data for Mosliciguat, and busy catalyst path for IMVT-1402, we like the set-up over the next 12+ months. While the stock has had quite a run over the last year, we think ROIV's core pipeline is unique in that it offers three uncorrelated shots on goal with Ph2+ assets where lead indications could drive blockbuster launches ahead of indication expansion optionality. Altogether, we model ~$9B in ROIV ownership-adjusted sales in 2037.

$ROIV now is a good time to make a offer ABUS Short-Squeeze Scenarios: $6.X–7: Squeeze begins $8.X–10: Strong short squeeze $12–15: Major squeeze + positive catalyst $20–25: Extreme squeeze $30+: Full-blown melt-up / exceptional catalyst With ~18M shares short, reduced share count and major potential catalysts, ABUS could move very quickly if shorts are forced to cover. A move above $8.X–10 could trigger a self-reinforcing cycle of short covering and momentum buying.

$ROIV Roivant announces trial of IMVT-1402 did not reach statistical significance Roivant announced topline results from Period 1 of Immunovant's proof-of-concept trial evaluating IMVT-1402 for the treatment of cutaneous lupus erythematosus, CLE. The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.